Expand MDCX Menu
MDCX MENU

MDCX Latest Press Releases

-- June 22, 2026 --

Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 Globe Newswire 7:30 AM

-- June 15, 2026 --

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome Globe Newswire 7:30 AM

-- June 11, 2026 --

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program Globe Newswire 7:30 AM

-- June 8, 2026 --

Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission Globe Newswire 7:30 AM

-- June 3, 2026 --

Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome Globe Newswire 8:00 AM

-- May 28, 2026 --

Medicus Pharma Announces $22 Million Non-Dilutive Financing Globe Newswire 8:00 AM

-- May 14, 2026 --

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:30 PM

-- May 6, 2026 --

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response Globe Newswire 7:30 AM

-- April 27, 2026 --

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill Globe Newswire 7:30 AM

-- April 17, 2026 --

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect in Gorlin Syndrome Globe Newswire 7:30 AM

-- April 15, 2026 --

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression Globe Newswire 7:30 AM

-- April 6, 2026 --

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention Globe Newswire 7:30 AM

-- April 1, 2026 --

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset Globe Newswire 7:30 AM

-- March 30, 2026 --

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate Globe Newswire 7:30 AM

-- March 26, 2026 --

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan Globe Newswire 7:30 AM

-- March 25, 2026 --

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update ACCESS Newswire 4:30 PM

-- March 18, 2026 --

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst ACCESS Newswire 7:30 AM

-- March 16, 2026 --

Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 Globe Newswire 7:30 AM

-- March 10, 2026 --

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum ACCESS Newswire 7:30 AM

-- March 9, 2026 --

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset Globe Newswire 7:30 AM

-- March 5, 2026 --

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200g Cohort Globe Newswire 7:30 AM

-- March 3, 2026 --

Medicus Pharma To Participate in the 38th Annual Roth Conference Globe Newswire 7:30 AM

-- February 12, 2026 --

Medicus Pharma on Bloomberg World ACCESS Newswire 7:30 AM

-- February 10, 2026 --

Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes